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ABSTRACT
Atherosclerosis (ATH) is an inflammation-mediated disease in which cell death underlies the
formation of lesions along the intima layer of vascular walls resulting in vessel narrowing,
decreased blood flow, and increased risk of lesion rupture leading to myocardial infarction and
stroke. The current study was undertaken to investigate whether inflammation in ATH can induce
pyroptosis in vascular smooth muscle cells (SMC’s). We therefore hypothesized that pyroptosis
occurs and is inhibited by bone morphogenetic protein 7 (BMP7). We examined SMC pyroptosis
at acute (D5) and midstage (D28) following disturbed flow-induced hemodynamic injury to the
vascular wall using our partial left carotid artery ligation (PLCA) model. ApoE -/- mice (11±1
week old) were divided into three groups: Sham, PLCA, PLCA+BMP7 (200µg/kg; i.v) and arterial
tissue was collected for immunohistochemical staining (IHC) and western blot (WB) analysis. At
D5 and D28, IHC data demonstrated that PLCA significantly upregulated Toll-like receptor 4
(TLR4) and NLRP3 inflammasome components (NLRP3 and Caspase-1), indicating the initiation
and activation of pyroptosis in SMC’s (p<0.05). Further, maturation of pro-IL-1β and pro-IL-18
released through cell membrane pores mediated by Caspase-11 were investigated. Our data shows
a significant increase at D5 and D28 in IL-1β, IL-18, and Caspase-11 expression following PLCA,
which was significantly improved upon treatment with BMP7 (p<0.05). Western blot analysis
supported these findings demonstrating initiation of pyroptosis via TLR4, upregulation of
inflammasome components (Caspase-1 and NLRP3), and release of proinflammatory cytokines,
IL-1β and IL-18 at D28, but not at D5. Overall, this study demonstrates that pyroptosis occurs in
vascular smooth muscle cells in our PLCA model and that BMP7 administration attenuates
pyroptosis significantly.
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CHAPTER ONE: INTRODUCTION
Atherosclerosis (ATH) is a chronic inflammatory condition characterized by the
accumulation of oxidized lipids (1), death of immune and vascular cells (4, 23, 51), and necrotic
plaque formation within arterial vessels resulting in a highly inflammatory environment with
restricted blood flow and predisposition to myocardial infarction and stroke (36). The
inflammatory events that underlie initiation of atherosclerosis (ATH) have been highly correlated
with endothelial cell dysfunction resulting from major risk factors including hyperlipidemia (67),
hypertension (44), and smoking (24). Currently, treatment strategies include surgery and
preventative therapies such as statins and lipid lowering pharmaceuticals; however, low-efficacy
among patients and prevalence of side effects limits their use (45, 52, 55). Therefore, it is of critical
importance to identify the major mechanisms of ATH progression and develop novel therapeutics
that target these pathways.
Atherosclerosis Initiation and Progression
It is known that hemodynamic injury to the vascular wall induces high shear stress and
alters the normal laminar flow of blood to a low and oscillatory state at atheroprone sites within
the vasculature (14, 15, 27). As a result, endothelial cells fail to maintain gap junction integrity
and are induced to express adhesion molecules and secrete proinflammatory factors (59).
Circulating monocytes in the blood have a high propensity to migrate along chemokine and
cytokine gradients to these adhesion molecules where they translocate into the subendothelial
space, undergo maturation into pro- or anti-inflammatory macrophages, and attempt to remove
damaged and dying cells through efferocytosis (62). However, the permeable subendothelial layer
following injury is prone to sequestration of enzymatically oxidized lipoproteins that facilitate
foam cell formation and necrotic lesions (53, 72, 79). In response, smooth muscle cells (SMC)
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become activated and migrate from the media to the intima layer of the vascular wall where they
secrete extracellular matrix proteins in attempt to stabilize the necrotic core against rupture (3).
However, death of SMC’s can result in intima thickening, plaque destabilization, lesion
progression, and increased cardiovascular risk (40).
Vascular Smooth Muscle Cells
SMC’s are responsible for vascular tone and secretion of extracellular matrix components
that stabilize vessels and regulate blood pressure (7, 48). In healthy vessels, smooth muscle cells
are atheroprotective and maintain a quiescent contractile state with low rates of proliferation;
however, in ATH, mechanical and chemical signals initiate a transition to a synthetic phenotype
characterized by increased migration and upregulated proliferation (39, 41). As a result, activated
SMC’s aberrantly proliferate and promote plaque progression by transmigrating from the medial
layer of the vessel to the intimal layer, where high concentrations of inflammatory molecules such
as nitric oxide, matrix metalloproteinases (MMP), and oxidized lipids activate cell death pathways
and foam cell formation (48, 49). Importantly, SMC’s are the major cell type that secretes
extracellular matrix components that stabilize mature lesions (4). The combination of extracellular
matrix (ECM)-degrading MMP’s secreted by inflammatory macrophages in addition to SMC death
increases the risk of lesion rupture, suggesting that inhibition of SMC death may be beneficial.
Pyroptotic Cell Death
Programmed cell death is necessary for homeostatic maintenance in healthy tissues;
however, cell death as a consequence of cell damage can induce a proinflammatory response that
dysregulates the dynamic process and results in disease. Vascular injury leading to endothelial
dysfunction and subsequent apoptotic and necrotic death of vascular and immune cells has been
reported as a major determinant of ATH progression (62). However, the role and contribution of
2

inflammation-mediated cell death via the pyroptotic pathway has only recently begun to be
investigated in chronic inflammatory diseases (34, 83).
Pyroptotic cell death is characterized by NLRP3 inflammasome activity, membrane pore
formation, cell swelling, and release of the proinflammatory cytokines, interleukin-1β (IL-1) and
interleukin-18 (IL-18) (37). Initiation of the pyroptotic pathway was first identified as a
mechanism stimulated by pathogen associated molecular patterns (PAMPS) in response to
bacterial infection (86). However, it is now known that it can be activated in response to sterile
inflammatory stimuli known as damage associated molecular patterns (DAMPS), as well (88).
There is evidence of numerous sources of DAMPS in ATH vessels that are known initiators of
pyroptotic cell death, including HMGB1 (78, 81), hyaluronan (76), ATP release by dying cells
(47), and oxidized lipoproteins (68). DAMPS are molecules secreted in response to cellular
damage that bind receptors of the toll-like receptor (TLR) family to induce NFkB transcriptional
programs necessary for production of inflammasome substrates (61, 92). The NLRP3
inflammasome, unique to pyroptosis, is a multiprotein complex composed of NLRP3, apoptosisassociated speck-like protein containing a caspase-recruitment domain (ASC), and pro-caspase1(30). Each component is necessary for inflammasome assembly, although the enzymatic activity
is mediated by caspase-1(74). Caspase-1 cleaves pro-interleukin-1β (IL-1) and pro-interleukin18 (IL-18), to active mature forms that are released through pores in the cell membrane to promote
inflammation (12, 57, 71, 88).
Bone Morphogenetic Protein 7
BMP’s are growth factors that belong to the transforming growth factor ß (TGF-ß)
superfamily which is known to regulate embryogenesis and tissue repair (19). 20 different BMP’s
have been characterized, although, the functions of each and their roles in different disease states
3

are still being elucidated (9, 10). Mechanistically, BMP’s regulate cellular functions by binding
type I and type II BMP receptors to induce signal transduction through the SMAD, MAPK p38,
and PI3K pathways (9, 54). BMP2 and BMP4 are commonly studied BMPs in ATH and have been
shown to be regulated by shear stress and flow rates in arteries (22). Oscillatory shear stress
induces BMP4 expression (69) while laminar flow inhibits it (17). In atherosclerotic ApoE -/mice, high levels of heat shock protein 70 has been shown to bind matrix gla proteins that prevent
BMP2 inhibition leading to plaque development (22). Interestingly, oxLDL has also been shown
to upregulate BMP2 expression in coronary endothelial cells and bind the TLR2/4 receptor
initiating the proinflammatory NFkB-ERK1/2 pathway (70). SMC’s overexpressing BMP2 have
also been shown to promote vascular calcification (18) while BMP7 was shown to inhibit it (31).
BMP7, also known as osteogenic protein-1, is endogenously expressed primarily in the kidney
(31) and has been reported to be anti-fibrotic and anti-inflammatory through regulating TGF- ßmediated Smad2/3 signaling and alternatively activating Smad1/5/8 (5, 8, 42, 80). Moreover, it is
known that BMP7 can inhibit the epithelial to mesenchymal transition (EMT) in a variety of
conditions including renal injury (89), hypoxia (91), and organ fibrosis (25). In injury-induced
vascular diseases, BMP7 has been reported to maintain the phenotype of vascular smooth muscle
cells while inhibiting proliferation, thereby suggesting that it may have a protective role (19). In
our lab, we have shown in vitro and in vivo, respectively, that BMP7 polarizes THP-1 (60) and
CD14+ve monocytes (65) into anti-inflammatory M2 macrophages thereby, downregulating the
production of proinflammatory cytokines and improving the ATH disease state.
Study Rationale and Aims
The anti-fibrotic and anti-inflammatory effects observed in previous studies suggests that
BMP7 may attenuate ATH through multiple mechanisms, including direct suppression of the
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pyroptotic pathway in SMC’s and/or downregulation of the inflammatory environment by
modulation of arterial cell phenotypes. Therefore, in the current study we induced ATH in ApoE
-/- mice using our partial left carotid artery ligation (PLCA) model to investigate the effects of
systemic administration of BMP7 on the inflammation-mediated cell death, pyroptosis, in vascular
smooth muscle cells of the left carotid artery.
For this study, we investigated the following aims:
 Aim 1: Assess atherosclerosis at an early stage (D5) to determine whether vascular smooth
muscle cells (SMC’s) undergo pyroptotic cell death mediated through the NLRP3
inflammasome and determine the therapeutic potential of BMP7 in modulating pyroptosis.
 Aim 2: Analyze pyroptosis at the midstage (D28) and determine if BMP7 reduces
inflammasome activation and pyroptotic death of SMC’s.
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CHAPTER TWO: METHODOLOGY
Partial Ligation of the Carotid Artery
The animal protocol used in the current study was approved by the University of Central
Florida Institutional Animal Care and Use Committee (IACUC). Mice were fed ad libitum with
normal laboratory rodent chow and housed in a pathogen-free facility under the care of veterinary
staff. Atherosclerosis was induced in B6.129P2-Apoetm1Unc/J (ApoE -/-) mice using the partial left
carotid artery ligation model (PLCA) as previously described (65, 66). 10 ± 1 week old mice were
distributed into 3 groups: (1) Sham, (2) PLCA, (3) PLCA+BMP7 and sedated using 3-4%
inhalatory isoflurane. Body weight was recorded and mice transferred to nose cone delivery of
isoflurane. Mice were arranged in the supine position on a heated pad and pain medication
(Buprenex, Henry Schein, cat#: 2284659) administered via intramuscular injection into the left
thigh. A depilatory agent (Nair) was used to remove hair along the ventral midline of the neck and
surgical scissors and tweezers were used to make a 4-5mm incision. Subsequent tissue was
separated using blunt dissection to expose the left carotid artery (LCA) and a 7/0 silk suture
(Ethicon, #768) was used to ligate 3 of the 4 branches of the LCA: the internal carotid, external
carotid, and occipital artery, leaving the superior thyroid artery unobstructed. In sham animals, the
suture was looped around the LCA, but not ligated. In PLCA animals, the suture was tied with
taught pressure. Following ligation, the incision was closed using a 4/0 polyprolene suture (CP
Medical #8629) and swabbed with betadine. Mice in the Sham and PLCA groups were
administered an intravenous injection of saline at 2 µl/g bodyweight (B.W.) or recombinant mouse
BMP7 treatment at an intravenous dosage of 200µg/kg B.W. (Bioclone, cat#PA-0401), as shown
in the schematic in figure 1. Injections were repeated for 2 subsequent days and mice were allowed
to recover for the duration of the timepoint, either D5 (acute) or D28 (midstage) post-surgery.
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Figure 1: Surgical and injection schedule. Sham or PLCA surgery was performed on adult male and female ApoE/- mice at D0 of the D5 (acute) or D28 (midstage) timepoint. Mice in groups receiving saline or BMP7 (200μg/kg)
treatment were administered via intravenous injection (i.v.) immediately following surgery and at D1 and D2,
subsequently. At the conclusion of the timepoint, analysis of systolic blood flow was performed, and mice
sacrificed for blood and tissue collection.

Left Carotid Artery Systolic Blood Velocity
Systolic blood velocity of the left carotid artery was determined using a Phillips Sonos
5500 Ultrasound system. As previously described, mice were anesthetized using 2-4% isoflurane
administered via nose cone and two-dimensional images were recorded using B-mode and vascular
settings (66). The ultrasound probe was placed along the left side of the mouse to visualize the
LCA and a minimum of 3 images were recorded for subsequent analysis. Within each frame, five
waveforms with the tallest systolic amplitude were qualitatively determined and quantitative
measurements of the distance from the centerline to the peak amplitude was assessed using the
caliper tool. Obtained values for each frame were averaged for each animal and combined to
determine the group average.

7

Immunohistochemistry
Following cervical dislocation, tissue containing the left carotid artery, right carotid artery,
trachea, and esophagus was collected by excising the throat at sites proximal and distal to the
ligation suture. Tissue was stored in 4% paraformaldehyde for 24-48 hours prior to washing in 1X
phosphate buffered saline (PBS). Tissues were processed in a Leica Tissue Processor (Leica,
#15053) overnight and embedded in paraffin blocks with the artery mounted vertically. 5 µm slices
were sectioned using a microtome (Microm, cat# HM325) and mounted on charged glass slides
(Fisher Scientific, USA, cat# 12-550-18). Slides were then heat fixed and deparaffinized using
xylene and a series of decreasing alcohol dilutions as previously described (65). Slides containing
the LCA were blocked for a minimum of 1 hour with 10% goat serum (Vector, cat# S-1000) in 1X
PBS. Vascular smooth muscle cells were immunostained with anti-alpha smooth muscle actin (2,
13) (Abcam, cat# ab5694) and pyroptotic markers for TLR4 (64, 85) (Abcam, cat# ab13556),
NLRP3 (11, 21) (Abcam, cat# ab214185), caspase-1 (35) (Abcam, cat# ab1872), interleukin-1β
(IL-1β) (32, 82) (Abcam, cat# ab9722), and interleukin 18 (IL-18) (33) (Abcam, cat# ab71495).
Primary antibodies were added at a 1:50 dilution in 10% goat serum (Vector Labs, cat# S-1000)
prior to overnight incubation at 4°C or a minimum of 1 hour at room temperature (RT). Following
incubation with the primary antibody, slides were decanted and washed with 1X PBS. Secondary
antibody, either Alexa Fluor 488 (65) (Fisher, A11008) for green fluorescence or Alexa Fluor 568
(65) (Fisher, A11011) for red fluorescence was prepared in 1X PBS and added for 1 hour at RT.
Slides were washed and cell nuclei counterstained with vectashield antifade mounting medium
with 4’, 6-diamidino-2-phenylindole (DAPI) (Vector Labs, cat# H-1200) prior to mounting with a
coverslip. Images for quantitative analysis were taken with the 20X objective using an Olympus
IX-70 microscope for D28 and an Nikon Eclipse 80i for D5. As an example, the percentage of
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vascular smooth muscle cells positive for each pyroptotic marker was determined using the
formula (Marker+ve Cells/Total alpha smooth muscle actin+ve Cells) *100.
Western Blot Analysis
To evaluate the levels of pyroptotic protein expression following PLCA surgery and BMP7
treatment, LCA tissue was collected immediately following sacrifice and assessed using Western
Blot (WB). Harvested LCA tissue was preserved in RNAL solution for 24 - 48hrs. Thereafter, the
RNAL solution was removed and tissues stored at -80 ̊C until homogenization and protein
extraction.

To

extract

proteins,

tissues

were

homogenized

via

sonication

in

radioimmunoprecipitation assay lysis buffer and centrifuged. Protein-containing supernatant was
transferred to new 0.6mL microcentrifuge tubes prior to performing our standard WB procedure
as described previously (65). In brief, the protein concentration of each sample was determined as
previously described using the Bradford Assay read at a wavelength of 595nm on a iMark
spectrophotometer (Biorad, cat# 1681135) (65). Equal amounts of protein (80µg) were separated
in either a 10% or 15% SDS-PAGE gel. Proteins were transferred to a polvinylidene fluoride
membrane using the semi-dry transfer method and blocked for at least 1 hour with 5% milk
prepared in 1X Tris Buffered Saline containing Tween-20 (TBS-T) as described previously (65).
Following blocking, 5mL of primary antibody prepared in 1X TBS-T were added and left to
incubate with shaking for 1hour at RT or overnight at 4oC. Protein expression levels of each
pyroptotic marker was determined by incubating the membranes with primary antibodies against
the markers: TLR4 (64, 85) (1:1000, Abcam, cat# ab13556), NLRP3 (11, 21) (1:1000, Abcam,
cat# ab214185), caspase-1 (35) (1:1000, Abcam, cat# ab1872), IL-1β (32, 82) (1:1000, Abcam,
cat# ab9722), and IL-18 (33) (1:1000, Abcam, cat# ab71495). ß-actin (1:1000, Cell Signaling,
#4967L) was used as a loading control. Following incubation, membranes were washed in 1X
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TBS-T and HRP conjugated anti-rabbit IgG (1:1000, Cell Signaling, cat# #7074S) secondary
antibody was prepared in 5% milk in 1X TBS-T and left to incubate for 1 hour at RT with shaking.
Subsequently, membranes were washed of excess secondary antibody and chemiluminescent
substrate solution (Thermo Scientific, cat# 32106) was added for a 3 minute incubation.
Membranes were placed in a cassette to exposed autoradiography film (MidSci, cat#BX810) prior
to development. Densitometry analysis based on band intensity was determined using ImageJ
(National Institute of Health, Version #1.39O) software as reported previously (60).
Statistical Analysis
Statistical analysis was performed using SigmaPlot software (Systat Software, San Jose,
CA) and assessed using one-way analysis of variance (ANOVA) and the Tukey test. Data was
determined to be significant when p<0.05 and data is presented as mean ± SEM.
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CHAPTER THREE: FINDINGS
Carotid Artery Ligation Increases Expression of TLR4 in Vascular Smooth Muscle Cells
To determine the extent to which TLR4 is expressed following LCA ligation in our PLCA
model, immunostaining of arterial sections was performed at the acute (D5) and midstage (D28)
timepoints. SMC’s were identified with the marker, anti-α-smooth muscle actin (α-SMA) as shown
in figure 2. Quantitative analysis of TLR4 expression, as shown in bar graphs B and D,
respectively, demonstrates that at the acute (D5) and midstage (D28) post-surgery, TLR4
expression is significantly increased in mice receiving LCA ligation in comparison to sham
animals (p<0.05). Previous studies have shown that oxLDL can induce inflammatory signaling
pathways through MyD88/NF-kB signaling, whereas mice deficient in TLR4 exhibited impaired
ATH plaque formation (87). Interestingly, our data demonstrated that administration of BMP7
significantly reduced (p<0.05) TLR4 levels at both timepoints suggesting that BMP7 may have an
inhibitory effect either through TLR4 activation directly or by inhibiting alternative BMPs, such
as BMP2, which may activate the inflammatory response (70). Furthermore, this data is in
agreement with previous reports by Bobacz et al. and Tan et al., that demonstrated the efficacy of
BMP7 in reducing expression of TLR4 following lipopolysaccharide stimulated pyroptosis (6, 73).
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Figure 2: TLR4 is upregulated in vascular smooth muscle cells following arterial ligation. Activation of the TLR4
receptor can initiate the intracellular signaling cascade that results in pyroptotic cell death. Representative images of
immunohistochemical staining for TLR4 expression at D5 (A) and D28 (C) shows that BMP7 administration to PLCA
mice significantly reduces TLR4 expression. TLR4 is shown in red (a, f, k), vascular smooth muscle cells in green (b,
g, l), DAPI in blue (c, h, m), and merged images (d, i, n). Scale bar = 100μm. White box indicates enlarged section
of merged images (e, j, o). Quantitative analysis in bar graph (B) (D5) and bar graph (D) (D28) shows increased
expression of TLR4 in SMC’s of PLCA mice vs. Sham animals, while treatment with BMP7 significantly reduced
this expression. * p<0.05 vs. Sham, #p<0.05 vs. PLCA, n=4 (all groups) (D5) and n = 6,5,5 (D28).

PLCA increases expression of NLRP3 Inflammasome Components
The NLRP3 inflammasome is a multiprotein complex composed of NLRP3, ASC, and
caspase-1, which assembles and enzymatically cleaves inflammatory cytokines that are released
through pyroptotic membrane pores (28). To establish the presence of the inflammasome in SMC’s
and directly characterize the cell death pathway as pyroptosis, immunostaining for the
characteristic components, NLRP3 and caspase-1, was performed on arterial tissue.
As shown in figure 3, NLRP3 expression in SMC’s is significantly increased at D5 and
D28 in the PLCA group in comparison to Sham animals; however, when PLCA mice were treated
with BMP7, these levels are significantly reduced (p<0.05). This data suggests that ligation-
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induces upregulation of NLRP3 transcription, which is necessary for inflammasome formation.
Conversely, the reduction seen in NLRP3 levels following BMP7 treatment suggests that BMP7
may initiate regulatory mechanisms that inhibit NLRP3 expression.

Figure 3: PLCA increases expression of NLRP3 at D5 and D28. Figure 3 shows representative images of
immunohistochemical staining and quantitative analysis of NLRP3 +ve vascular smooth muscle cells at D5 (A and B)
and D28 (C and D). NLRP3 is shown in red (a, f, k), vascular smooth muscle cells in green (b, g, l), DAPI in blue (c,
h, m), and merged images (d, i, n). Scale bar = 100μm. White box indicates enlarged section of merged images (e, j,
o). D5 and D28 quantitative analysis shown in bar graph (B) and (D), respectively, show that LCA ligation
significantly increases the expression of NLRP3 vs. sham mice. However, upon administration of BMP7, these levels
are reduced significantly at both timepoints indicating that BMP7 is capable of reducing the activation of NLRP3
necessary to form the inflammasome complex. * p<0.05 vs. Sham, #p<0.05 vs. PLCA, n=4,6,7 (D5) and n = 7,5,5
(D28).

In agreement with the trends observed in SMC’s expressing NLRP3, we show that at D5
and D28 the percentage of SMC’s expressing caspase-1 is significantly increased in PLCA vs.
sham (figure 4). However, mice treated with BMP7 demonstrated a significant reduction in these
levels in comparison with PLCA (p<0.05). Altogether, these results indicate that arterial ligation
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increases expression of the NLRP3 inflammasome components necessary to mediate pyroptotic
cell death and that BMP7 demonstrates therapeutic ability in reducing these levels.

Figure 4: BMP7 reduces Caspase-1 expression at D5 and D28. Caspase-1 possesses the enzymatic activity of the
NLRP3 inflammasome resulting in the cleavage of inflammatory cytokines. Panels (A) and (C) show representative
immunofluorescent images of Caspase-1 expression at D5 and D28, respectively. Caspase-1 is shown in red (a, f, k),
vascular smooth muscle cells in green (b, g, l), DAPI in blue (c, h, m), and merged images (d, i, n). Scale bar = 100μm.
White box indicates enlarged section of merged images (e, j, o). Bar graphs (B) and (D) show quantitative analysis of
Caspase-1+ve vascular smooth muscle cells indicating that LCA ligation significantly increased the expression of
Caspase-1, which is reduced following treatment with BMP7. * p<0.05 vs. Sham, #p<0.05 vs. PLCA, n=4,4,3 (D5)
and n = 7,6,6 (D28).

To corroborate the findings of our IHC data, we performed western blot analysis on
midstage (D28) arterial tissue for TLR4, NLRP3 and caspase-1. Our findings show that protein
expression is significantly increased in the PLCA group vs. sham (p<0.05) as shown in figure 5.
However, administration of BMP7 significantly reduced these levels in comparison to PLCA.
Taken together, this data supports the findings of our IHC staining which is indicative of
pyroptosis initiation and activation. Importantly, the results of western blot analysis performed
on arterial tissues at D5 (data not shown) were inconclusive due to low protein expression levels.
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It is possible that distinguishable differences may be observed at the transcriptional level as
determined in the future using RT-PCR, but not at the translational level as necessary for western
blot analysis presently.

Figure 5: BMP7 reduced NLRP3 inflammasome initiation and activation at D28. Densitometric analysis of LCA
tissue demonstrated that PLCA increases the expression of TLR4 (A), NLRP3 (B), and Caspase-1 (C); however,
treatment with BMP7 significantly reduced these levels as shown in the bar graphs in Figure 7. * p<0.05 vs. Sham,
#p<0.05 vs. PLCA, TLR4 (n=5-6), NLRP3 (n=4-5) and Caspase-1 (n=4-5).

BMP7 Reduces Proinflammatory IL-1β and IL-18
Inflammasome activation results in the cleavage of precursor proteins, pro-IL-1β and proIL-18, producing mature forms that are released through membrane pores characteristic of
pyroptotic cells death. To understand the effects of arterial ligation-induced ATH on inflammatory
cytokine expression, we performed immunostaining of arterial SMC’s for IL-1β and IL-18
expression. As shown in figure 6, the levels of IL-1β+ve SMC’s are significantly upregulated in the
PLCA group vs. sham animals at both timepoints, D5 and D28 (p<0.05) indicative of a
proinflammatory response. However, these levels were significantly reduced following BMP7
treatment (p<0.05).
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Figure 6: Carotid artery ligation increases proinflammatory IL-1β. Inflammasome activation cleaves pro- IL-1β to
a mature form that gets released through the cell membrane promoting inflammation. Figure 5 shows that BMP7
administration significantly reduces the levels of IL-1β+ve vascular smooth muscle cells following carotid artery
ligation. Representative images at D5 is shown in panel (A) and D28 as shown in panel (C). Quantitative analysis of
IL-1β at D5 and D28 is shown in bar graphs (B) and (D), respectively. IL-1β is shown in red (a, f, k), vascular smooth
muscle cells in green (b, g, l), DAPI in blue (c, h, m), and merged images (d, i, n). Scale bar = 100μm. White box
indicates enlarged section of merged images (e, j, o). Quantitative analysis in bar graph (B) (D5) and bar graph (D)
(D28) shows increased expression of IL-1β in SMC’s of PLCA mice vs. Sham animals, while treatment with BMP7
significantly reduced this expression. * p<0.05 vs. Sham, #p<0.05 vs. PLCA, n=5,5,8 (D5) and n = 7,5,6 (D28).

We further evaluated the effects of BMP7 on IL-18 expression following PLCA. As shown
in figure 7, our IL-18 data is in accordance with the trend observed in IL-1β. Mice receiving arterial
ligation demonstrated a significant increase in IL-18 expression in SMC vs. sham (p<0.05, while
BMP7 treatment significantly reduced these levels in comparison to PLCA (p<0.05).
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Figure 7: IL-18 expression is reduced in smooth muscle cells following BMP7 treatment. Representative

images of immunohistochemical staining for IL-18+ve vascular smooth muscle cells at D5 (A) and D28 (C) shows
that BMP7 administration to PLCA mice significantly reduces IL-18 expression. IL-18 is shown in red (a, f, k),
vascular smooth muscle cells in green (b, g, l), DAPI in blue (c, h, m), and merged images (d, i, n). Scale bar =
100μm. White box indicates enlarged section of merged images (e, j, o). Quantitative analysis in bar graph (B)
(D5) and (D) (D28) shows increased expression of IL-18 in PLCA mice vs. Sham animals, while treatment with
BMP7 significantly reduced this expression. * p<0.05 vs. Sham, #p<0.05 vs. PLCA, n=3,4,4 (D5) and n = 6,5,6
(D28).

To further confirm our IHC data, western blot was performed for caspase-11, IL-1β and
IL-18 as shown in figure 8. Caspase-11 is traditionally associated with non-canonical
inflammasome activation in response to gram negative bacteria. Importantly, caspase-11 is known
to mediate cleavage of gasdermin-D (75) that mediates pore formation leading to cell swelling and
release of proinflammatory cytokines (75, 86). Densitometric analysis of arterial tissue at D28
post-surgery shows that caspase-11 is significantly increased following arterial ligation (p<0.05).
However, BMP7 significantly reduced this expression vs. PLCA (p<0.05). Moreover, this trend
was also observed in densitometric analysis of IL-1β and IL-18. PLCA significantly increased
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(p<0.05) the expression of IL-1β and IL-18 at D28, while BMP7 significantly reduced these levels
(p<0.05).

Figure 8: Effect of BMP7 on pyroptotic pore formation and proinflammatory cytokines at D28. Western blot

of arterial tissue harvested at D28 was quantitatively assessed for protein expression levels of caspase-11 (A),
and proinflammatory cytokines, IL-1β (B) and IL-18 (C), using densitometric analysis. * p<0.05 vs. Sham,
#p<0.05 vs. PLCA, Caspase-11 (n=4-5), IL-1β (n=4, all groups) and IL-18 (n=4, all groups).

BMP7 Improves Systolic Blood Velocity
Systolic blood velocity through the left carotid artery is indicative of arterial function and
ATH disease progression. Smooth muscle cells regulate vasoconstriction and vasodilation of the
arterial wall to control systolic blood flow. To understand the effects of BMP7 treatment following
arterial ligation, we analyzed systolic blood velocity. As shown in figure 9, systolic blood velocity
was significantly reduced (p<0.05) in PLCA mice at the acute (D5) and midstage (D28) timepoints
while treatment with BMP7 demonstrated a significant improvement (p<0.05). This data is in
agreement with previous studies in our lab demonstrating BMP7s ability to improve blood flow
velocity (65).
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Figure 9: BMP7 improves systolic blood velocity following carotid artery ligation. Images in Panel (A) (D5)

and (C) (D28) show representative images of systolic blood flow recorded in B mode using transesophageal
ultrasound. Bar graph (B) and (D) shows quantitative analysis of systolic velocity measured in cm/s. * p<0.05
vs. Sham, #p<0.05 vs. PLCA, n=3,5,4 (D5) and n = 6 (all groups) (D28).
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CHAPTER FOUR: CONCLUSION
ATH initiates and chronically progresses as a consequence of hemodynamic injury to the
vascular wall resulting from changes in the normal laminar flow of blood. A major consequence
of vascular injury is endothelial dysfunction which is known to initiate loss of vascular integrity,
recruit immune cells, and increase proliferation and migration of vascular SMC’s. These events
are further intensified by defective efferocytosis and impaired autophagy that stimulates cell death
and results in vessel lesions (36, 48).
In recent years, novel therapies aimed at immunomodulation using protein therapeutic has
gained significant interest and validation. Historically, focus has been on modulating macrophages
due to their role in inflammatory cytokine release, phagocytosis, and foam cell formation, leading
to establishment of the necrotic core. However, targeting other cell populations, such as SMCs,
known to play major roles in lesion stabilization may present a novel approach to ATH modulation
with equal or greater efficacy.
SMC’s sense and respond to the mechanical and biochemical signals produced by damaged
cells following vascular injury. This initiates upregulated proliferation and migration toward the
source of inflammatory stimuli. However, the effects of this are dynamic and multifold. While
SMC’s are atheroprotective through secretion of ECM components, they remain sensitive to the
inflammatory environment of atherosclerotic vessels. Under high concentrations of DAMPS and
in the presence of oxLDL, SMC’s initiate cell death signaling mechanisms and undergo foam cell
formation that subsequently contributes to vessel lesions.

Therefore, elucidation of the

inflammatory events and implications of cell death in ATH may present opportunities to develop
novel therapies.
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In the present study, we investigated pyroptosis, an NLRP3 inflammasome-mediated cell
death, in SMC’s following ATH induction in our in vivo PLCA model of disturbed blood flow and
further evaluated the therapeutic potential of BMP7.
Vascular injury stimulates TLR4 mediated transcriptional programs that activate the
NLRP3 inflammasome upstream of pyroptotic cell death. Previous studies have shown that
macrophages produce upregulated levels of DAMPS and proinflammatory cytokines in response
to hemodynamic injury, thereby providing a source of signaling molecules capable of engaging
the TLR4 receptor in vascular SMC’s (58). TLR4 is a receptor expressed by macrophages,
endothelial cells, and SMC’s, and regulates specific intracellular signaling mechanisms in response
to ligand interaction (46, 56, 90). Previous studies have shown that TLR4 mediates cell death in a
variety of conditions, including ATH (26, 77, 84). Data presented in the current study demonstrates
that initiation of the pyroptotic signaling cascade, mediated through TLR4 activation, is
significantly upregulated in ApoE -/- mice that received arterial ligation at both, the acute and
midstage, timepoints. However, PLCA mice that received BMP7 treatment showed a significant
reduction in TLR4 in comparison to PLCA. A possible rationale for this observation is that BMP’s
are known to have counterregulatory effects in a variety of physiological conditions. For example,
BMP2/4 are known to be highly expressed in atherosclerotic vessels and are proinflammatory and
pro-fibrotic (5, 8, 42, 80). Therefore, it is conceivable that BMP7 regulates other BMP’s, thereby
suppressing TLR4 expression. Alternatively, BMP7 has been shown to modulate immune cells to
an anti-inflammatory phenotype (65). The dependence of DAMP secretion by inflammatory
immune cells for activation of TLR4 suggests that the reduced levels seen in SMC’s may be a
secondary effect of immune cell phenotypic modulation (65).
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Downstream of TLR4, pyroptotic cell death requires activity of the NLRP3 inflammasome,
which is composed of NLRP3, ASC, and Caspase-1 (30). We therefore, investigated the effect of
BMP7 on NLRP3 and caspase-1 following PLCA. Our IHC data demonstrates that PLCA
increases expression of NLRP3 at the acute and midstage timepoint, while administration of BMP7
reduced these levels significantly. Interestingly, the reduced expression levels suggest that BMP7
may have a regulatory role on pathway intermediates. The transcriptional program necessary for
NLRP3 gene products is dependent on smad signaling (9, 54). BMP7 is known to interact with the
type II BMP receptor and activate inhibitory smads (9, 54). The reduced levels observed following
BMP7 administration could be the result of decreased TLR4 initiation as previously discussed, or
alternatively through inhibitory smad signaling.
Moreover, inflammasome activation promotes cysteine cleavage of precursor
proinflammatory cytokines, pro-IL-1β and pro-IL-18, which are released through caspase-11
mediated membrane pores (28, 38, 50, 63). Our data demonstrates that PLCA increases the
expression of IL-1β and IL-18, while BMP7 reduced these levels. This observed increase in
proinflammatory cytokine expression is consistent with other studies on endothelial cells and
macrophages investigating pyroptotic cell death (29, 47). Furthermore, caspase-11 is not
traditionally seen in canonical inflammasome signaling as seen in sterile inflammation, its
presence may indicate compensatory mechanisms or pathway crosstalk. Further studies will be
needed to clarify its role. Taken together, data shows that arterial injury upregulates proteins that
mediate pore formation (caspase-11) in the cell membrane, increase proinflammatory cytokine
expression (IL-1β and IL-18), and demonstrates that BMP7 is capable of reducing these levels
significantly. Our functional data demonstrated that PLCA significantly reduced systolic blood
flow at D5 and D28 in comparison to Sham animals. However, BMP7 was able to attenuate this
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decrease and demonstrated improved systolic flow rates following treatment. This data is
consistent with previous studies in our lab (65). Importantly, this data also supports the therapeutic
effects of BMP7 on SMC’s which functionally regulate vascular tone (7, 48). The observed
increase in flow rate supports that BMP7 functionally benefits SMC’s.
As an additional rationale for the mechanistic effects of BMP7 on SMC’s, previous studies
have shown that activated smooth muscle cells can phenotypically switch in response to lipid
loading and environmental factors (4). Cell lineage tracing studies have suggested that SMC’s can
switch to a macrophage-like phenotype that is proinflammatory and migratory (4). TGF- β is a
known factor that regulates phenotypic switching, as in endothelial to mesenchymal transition
observed in vascular cells (19). Importantly, BMP7 has been reported to inhibit TGF-β signaling
in smooth muscle cells following vascular injury. Dorai et al., investigated SMC proliferation,
migration, and expression of SMC-specific markers following administration of BMP7 in-vitro
and demonstrated that BMP7 stimulates Smad 6 expression to inhibit TGF-β signaling (20).
Therefore, SMC’s maintain a quiescent state that prevents phenotypic switching, upregulated
proliferation, and cell death that contributes to lesion formation (16).
Furthermore, in contrast to other in vivo models of ATH in which a high-fat diet is used to
induce ATH, our surgical model is more representative of individuals that develop ATH without
implications of lifestyle (43). Using this model we have previously investigated the role of BMP7
on infiltrating monocytes following arterial ligation (65). Given the dynamic relationship between
immune cells and SMC’s within the ATH vessel, an alternative perspective for the observed
reduction in SMC pyroptosis could be the result of immune cell modulation. Our lab has previously
shown that BMP7 can polarize monocytes into anti-inflammatory M2 macrophages through
activation of the SMAD-PI3K-Akt-mTOR pathway (60). Macrophages are a major cellular source
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of DAMPS and proinflammatory cytokines following vascular injury (58). Polarizing monocytes
to the anti-inflammatory phenotype has been shown previously by our lab to reduce the expression
of proinflammatory cytokines (IL-6, MCP-1, and TNF-α), while increasing anti-inflammatory
cytokine, IL-10 (65). In promoting M2 phenotypic differentiation with BMP7, levels of
proinflammatory M1 macrophages are reduced. As a result, there is a reduction in the levels of
proinflammatory signaling molecules that interact with TLR4 receptor necessary to initiate the
pyroptotic cascade.
The data presented in this study in coordination with others that suggest the beneficial
effects observed following administration of BMP7 in atherosclerotic ApoE -/- mice may be
multifold and result from mechanisms such as: a) decreasing pyroptotic cell death of SMC’s
directly through modulation of TLR4 or NLRP3 inflammasome activity; b) inhibiting the
phenotypic switching of SMCs so that a quiescent state is maintained; and/or c) promoting the
polarization of resident and infiltrating immune cells to an anti-inflammatory phenotype that
decreases SMC pyroptosis through an indirect mechanism (4, 65). In conclusion, our data supports
that pyroptosis occurs in vascular smooth muscle cells at both the acute (D5) and midstage (D28)
and further, we demonstrate evidence of the therapeutic potential of BMP7 in ATH.
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